Contribution by NRF2 Upregulation to Lung Carcinogenesis and the Possible Therapeutic Value of NRF2 Inhibition by GSK-3 (Joint with Universities of St Andrews, Edinburgh and Pennsylvania)

Project Details

Effective start/end date1/05/1631/10/19


  • Medical Research Council (MR/N009851/1): £854,266.00

Research Output

  • 1 Citation (Scopus)

    Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

    Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A-L., Kensler, T. W. & Dinkova-Kostova, A., Apr 2019, In : Nature Reviews Drug Discovery. 18, 4, p. 295-317 23 p.

    Research output: Contribution to journalReview article

    Open Access
  • 122 Citations (Scopus)
    193 Downloads (Pure)

    A partnership with the proteasome: the destructive nature of GSK3

    Robertson, H., Hayes, J. D. & Sutherland, C., Jan 2018, In : Biochemical Pharmacology. 147, p. 77-92 16 p.

    Research output: Contribution to journalArticle

    Open Access
  • 16 Citations (Scopus)
    183 Downloads (Pure)